IDEAYA Biosciences, Inc. IDYA

IDEAYA Biosciences, a pre-commercial precision-oncology company with about $1.24 billion in cash and equivalents, widened quarterly net loss to $112.5 million as R&D accelerates toward multiple Phase 3 and immuno-oncology programs. The core plan: de-risk the pipeline with non-dilutive partner funding, notably Servier, which covers international development costs while IDEAYA keeps 100% of US commercial rights. A key milestone arrived: first patient dosed in OptimUM-11, a global Phase 3 trial of darovasertib with crizotinib as adjuvant therapy for primary uveal melanoma, targeting ~450 patients. Enrollment is open to all HLA types, broadening the addressable market. OptimUM-02 previously showed a PFS benefit (6.9 vs 3.1 months, HR 0.42). IDEAYA has a rolling NDA under RTOR with Fast Track/Orphan/Breakthrough designations. OS data for OptimUM-02 remains immature; margins are pressured by R&D, and international rights may limit total revenue. Short interest ~12%; forward P/E about 4.65. Bulls face regulatory risk and cash burn. Progress from the OptimUM-11 program and the Servier partnership could materially alter IDEAYA's future profitability if regulatory approval is achieved, though near-term OS data remain uncertain and cash burn continues.

IDEAYA Biosciences and Servier dosed the first patient in the global Phase 3 OptimUM-11 registrational trial evaluating darovasertib plus crizotinib as adjuvant therapy for uveal melanoma. Phase 3 start for lead asset darovasertib advances IDEAYA toward potential approval and revenue in uveal melanoma.

IDEAYA Biosciences completed a successful FDA Type C meeting for IDE849, a DLL3 TOP1 ADC, focusing on Phase 3 registrational trial design aimed at accelerated and full approval for extensive stage small cell lung cancer. FDA alignment on Phase 3 design for IDE849 positions the company for potential accelerated approval in extensive stage small cell lung cancer.

IDEAYA Biosciences announces clinical collaboration with Genentech for MTAP-deleted KRAS G12D-mutant pancreatic cancer. Collaboration with Genentech advances IDEAYA pipeline in pancreatic cancer and supports valuation growth.

IDEAYA Biosciences reported a wider loss alongside a new Roche partnership that could alter its bull case. Roche partnership signals major strategic alliance likely to shift development trajectory and investor sentiment despite wider losses.

IDEAYA Biosciences reported second quarter 2026 financial results and provided a business update. Quarterly financial results with business updates can shift investor views on financial health and pipeline progress.

IDEAYA Biosciences initiates Part 2 monotherapy expansion in Phase 1/2 study of IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, in MTAP-deleted pancreatic and lung cancers. IDE892 advancement into Phase 1/2 expansion for MTAP-deleted cancers marks a key clinical milestone likely to boost IDEAYA valuation and pipeline momentum.

IDEAYA Biosciences initiates Phase 1/2 clinical combination study of IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, in MTAP-deleted pancreatic and lung cancers. Phase 1/2 trial start advances targeted oncology pipeline with potential to influence competitive positioning.

IDEAYA Biosciences (IDYA) forms clinical partnership with Roche for IDE892 efficacy study. Roche partnership advances IDE892 development and strengthens IDEAYA's clinical and market position.

IDEAYA Biosciences priced a $300 million public offering of common stock and pre-funded warrants. The offering supplies substantial capital for operations and R&D but increases share count and dilutes existing holders.

IDEAYA Biosciences proposes public offering of common stock and pre-funded warrants to raise capital. Public offering raises funds for operations while diluting shares and pressuring near-term stock price.

IDEAYA Biosciences' Darovasertib posts positive Phase 2/3 trial results, triggering a partnership deal with Roche that directly boosts shareholder value through expanded oncology development and commercialization prospects. Phase 2/3 success plus Roche deal creates transformative oncology pipeline momentum and major revenue upside for IDEAYA.

IDEAYA Biosciences announces clinical collaboration with Roche targeting MTAP-deleted RAS-mutant pancreatic cancer. Roche partnership advances IDEAYA pipeline and bolsters competitive position in oncology.

IDEAYA Biosciences and Servier released complete Phase 2/3 OptimUM-02 trial data for darovasertib combination in first-line HLA*A2:01 negative metastatic uveal melanoma at ASCO late-breaking presentation. Positive registrational trial data advances darovasertib toward potential approval and strengthens IDYA pipeline.

IDEAYA Biosciences highlighted Darovasertib clinical win and FDA review pathway at oncology summit. Positive Darovasertib data plus clear FDA path signals major pipeline and regulatory progress for IDEAYA.

IDEAYA Biosciences advances darovasertib toward FDA filing with plans for active 2026 development milestones. Darovasertib FDA filing progress marks major regulatory step likely to shift IDEAYA trajectory and investor sentiment.

IDEAYA Biosciences advances its melanoma drug toward NDA submission after reporting strong clinical trial data. Positive trial data and NDA progress signal major catalyst for IDEAYA's drug pipeline and valuation.

IDEAYA Biosciences (IDYA) valuation reassessed upward after positive Phase 2/3 results for Darovasertib in uveal melanoma and FDA Real-Time Review designation, highlighting strong efficacy data and accelerated approval pathway. Positive Phase 2/3 Darovasertib results and FDA Real-Time Review fundamentally enhance IDYA's path to approval and long-term oncology market position.

IDEAYA Biosciences, Inc. (IDYA) reported a Q1 loss and missed revenue estimates. Q1 loss and missed revenue estimates indicate weaker financial performance, likely causing moderate short-term pressure on stock price and investor sentiment.

IDEAYA Biosciences reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business update moderately influence financial performance and investor sentiment.

Twenty-three hedge funds held positions in IDEAYA Biosciences (IDYA) in Q3 2024, up from 21 quarters prior, highlighting its appeal amid a precision oncology pipeline including darovasertib and IDE397, with strong clinical progress and undervaluation potential driving buy recommendations. Rising hedge fund interest and pipeline advancements signal moderate positive influence on investor sentiment and stock performance.

IDEAYA Biosciences will initiate New Drug Application submission for darovasertib from the OptimUM-02 trial under FDA's Oncology Center of Excellence Real-time Oncology Review (RTOR) Program. Initiating NDA under RTOR from Phase 3 trial accelerates path to potential approval and commercialization, significantly impacting IDYA's market position and investor sentiment.

Wedbush raised its price target for IDEAYA Biosciences (IDYA) following positive topline readout from the OptimUM-02 trial. Positive OptimUM-02 trial readout led to Wedbush increasing IDYA's price target, signaling major boost to investor sentiment and clinical prospects.

IDEAYA Biosciences announces late-breaking abstract oral presentation at ASCO 2026 featuring complete data from Phase 2/3 registrational OptimUM-02 trial of darovasertib plus crizotinib for first-line HLA*A02-negative metastatic uveal melanoma. Presentation of complete registrational Phase 2/3 trial data at ASCO 2026 signals potential regulatory approval pathway and significant upside for IDEAYA's stock and pipeline.

IDEAYA Biosciences announced OptimUM-02 trial data: darovasertib combined with crizotinib doubled progression-free survival in uveal melanoma patients compared to historical controls. Doubling PFS in phase 2 uveal melanoma trial significantly advances IDYA's lead oncology program, enhancing competitive positioning and investor sentiment.

IDEAYA Biosciences and Servier announce positive topline results from the Phase 2/3 registrational OptimUM-02 trial of darovasertib combined with crizotinib as first-line therapy for HLA-A*02:01-negative metastatic uveal melanoma. Positive topline data from registrational Phase 2/3 trial positions darovasertib for potential approval and commercialization in metastatic uveal melanoma, transforming IDYA's oncology pipeline and market prospects.

IDEAYA Biosciences (IDYA) shares surged 14% due to positive developments in its cancer therapy pipeline. 14% share price jump reflects significant positive catalyst impacting IDYA's market performance and investor sentiment.

Ideaya Biosciences (IDYA) stock surges on promising clinical results for a treatment targeting hard-to-treat melanoma. Promising results for hard-to-treat melanoma treatment signal major pipeline advancement and boost investor sentiment for IDYA.

IDEAYA Biosciences stock surged 15% after positive results from a clinical trial of its eye cancer therapy. Positive eye cancer therapy trial results triggered a 15% stock jump, indicating major progress in pipeline that could boost investor sentiment and competitive positioning.

IDEAYA Biosciences will announce topline results from its Phase 2/3 OptimUM-02 trial in metastatic uveal melanoma on April 13, 2026. Topline results from a pivotal Phase 2/3 trial in metastatic uveal melanoma could fundamentally redefine IDEAYA's oncology prospects and stock trajectory.